Skip to the answer

Selexipag

Selexipag is a prostacyclin receptor agonist used to treat pulmonary arterial hypertension (PAH, high blood pressure in the lungs' arteries) and to delay disease progression and reduce the risk of hospitalization for PAH.

Brand names UptraviUPTRAVI Titration PackSelexipag TITRATION PACK
Drug class Prostacyclin Receptor Agonist
Rx Forms 3
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 3 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Other forms & routes:
Injection
Selexipag at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Selexipag (Uptravi) is a specialist medicine for pulmonary arterial hypertension (PAH, high blood pressure in the lungs’ arteries) that acts on the same receptor as the body’s own prostacyclin, a natural vessel-relaxing signal, and it is usually added to other PAH medicines; it has been on the U.S. market since about 2015 and is now available generically. Side effects are common, mostly headache, diarrhea, nausea, jaw pain and flushing, and they peak while the dose is being stepped up. Report new or worsening shortness of breath right away, since fluid in the lungs can point to pulmonary veno-occlusive disease, a related blockage of the small lung veins.

Clinical pearls

  • Swallow the tablets whole without splitting or crushing, and taking them with food can make them easier to tolerate.
  • Never take it with gemfibrozil, a triglyceride medicine, because it greatly raises the active form of selexipag.
  • Clopidogrel, deferasirox or teriflunomide raise selexipag levels, so dosing drops to once daily; rifampin does the opposite.
  • Mention a racing heart, heat intolerance or unexplained weight loss, since an overactive thyroid has been reported with selexipag.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet, Capsule, Injection
Earliest FDA record2015
Companies listing it with the FDA3
FDA label last updatedMay 28, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Selexipag, written from its FDA label.

What Selexipag is used for

▾

Selexipag is used for pulmonary arterial hypertension.

  • PAH (WHO Group I): to delay disease progression and reduce the risk of hospitalization for PAH.
  • Uptravi is approved for adults and for children aged 2 years and older. In children, it reduces NT-proBNP (a heart strain marker) and is expected to delay progression and reduce hospitalization.
  • Selexipag tablets (generic) are labeled for PAH in the evidence provided.
  • Effectiveness of the tablets was shown in a long-term study of adults with WHO Functional Class II–III symptoms.

How Selexipag works

▾

Selexipag switches on the prostacyclin receptor (IP receptor). The body turns it into an active form, about 37 times as potent, using an enzyme called carboxylesterase 1. Both forms target the IP receptor and not other related receptors.

Selexipag dosage

▾

Tablets are taken by mouth twice daily. Swallow them whole, and take them with food if that helps you tolerate them. Doses are raised gradually, usually weekly, to the highest tolerated dose.

  • Uptravi for injection is given by IV infusion twice daily, with the dose set from your current tablet dose.
  • Children's doses depend on body weight.
  • Moderate liver impairment or certain interacting medicines may call for once-daily dosing.

Follow your prescriber and the product label.

Dosing details from the FDA-approved label

From the Selexipag prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Adult patients (UPTRAVI tablets)
    • Starting dose 200 mcg orally twice daily
    • Increase in increments of 200 mcg orally twice daily, usually at weekly intervals, to the highest tolerated dose
    • Maximum: 1,600 mcg orally twice daily
    • Tolerability may be improved when taken with food; if a dose cannot be tolerated, reduce to the previous tolerated dose; swallow whole, do not split or crush
  • Pediatric patients two years and older, 9 kg to less than 25 kg
    • Starting dose 100 mcg orally twice daily
    • Titration increments 100 mcg orally twice daily
    • Maximum: 800 mcg orally twice daily
    • Dosing based on body weight
  • Pediatric patients two years and older, 25 kg to less than 40 kg
    • Starting dose 150 mcg orally twice daily
    • Titration increments 150 mcg orally twice daily
    • Maximum: 1,200 mcg orally twice daily
    • Dosing based on body weight
  • Pediatric patients two years and older, 40 kg to less than 50 kg
    • Starting dose 150 mcg orally twice daily
    • Titration increments 150 mcg orally twice daily
    • Maximum: 1,600 mcg orally twice daily
    • Dosing based on body weight
  • Moderate hepatic impairment
    • Starting dose once daily, increase in increments of the starting dose once daily at weekly intervals to the maximum allowed or highest tolerated dose
    • Once daily dosing
  • Adult patients (UPTRAVI for injection)
    • Dose is determined by the patient's current dose of UPTRAVI tablets
    • Administer by intravenous infusion, twice daily
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Adult patients: UPTRAVI tablets starting dose: 200 mcg orally twice daily. Increase the dose by 200 mcg orally twice daily at weekly intervals to the highest tolerated dose up to 1,600 mcg orally twice daily. ( 2.1 ) Pediatric patients: See Full Prescribing Information for recommended starting dose, titration increments, and maximum allowed dose based on body weight category. ( 2.1 ) Maintenance dose is determined by tolerability. ( 2.1 ) Moderate hepatic impairment: Starting dose once daily, increase in increments of the starting dose once daily at weekly intervals to the maximum allowed or highest tolerated dose. ( 2.6 ) Adult patients: UPTRAVI for injection dose is determined by the patient's current dose of UPTRAVI tablets. Administer UPTRAVI for injection by intravenous infusion, twice daily. ( 2.2 ) See Full Prescribing Information for instructions on preparation and administration. ( 2.3 , 2.4 ) 2.1 Recommended Dosage and Administration for UPTRAVI Film-coated Tablets Adult Patients The recommended starting dosage of UPTRAVI tablets is 200 mcg given orally twice daily. Tolerability may be improved when taken with food [see Clinical Pharmacology (12.3) ] . Increase the dose in increments of 200 mcg orally twice daily, usually at weekly intervals, to the highest tolerated dose up to 1,600 mcg orally twice daily. If a patient reaches a dose that cannot be tolerated, the dose should be reduced to the previous tolerated dose. Swallow the UPTRAVI tablets whole. Do not split or crush the tablets. Pediatric Patients Two Years and Older The recommended starting dose of UPTRAVI is determined based on the patient's body weight and is given orally twice daily. The recommended UPTRAVI starting doses, titration increments, and maximum allowed doses based on body weight categories in pediatric patients are shown in Table 1.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Selexipag side effects

▾

Most side effects are more frequent while the dose is being raised.

Common side effects

  • Headache
  • Diarrhea
  • Nausea and vomiting
  • Jaw pain
  • Muscle aches (myalgia)
  • Pain in arms or legs
  • Flushing
  • Abdominal pain (more often in children)
  • Joint pain, anemia, decreased appetite and rash were also seen more often than with placebo in adults

When to get medical help

  • Call your doctor right away if you have signs of fluid in the lungs (pulmonary edema), such as new or worsening shortness of breath. This may point to pulmonary veno-occlusive disease, and treatment may need to stop.
  • Tell your doctor if side effects become hard to tolerate, since the dose may need to be lowered.
  • Tell your doctor about symptoms of an overactive thyroid (hyperthyroidism), which was seen in about 1% of adults on the tablets.
  • Get medical help for an allergic reaction to selexipag or any of its ingredients.

Selexipag warnings and precautions

▾

The biggest warning is pulmonary edema in people with pulmonary veno-occlusive disease. If it is confirmed, selexipag should be stopped.

  • Do not combine with strong CYP2C8 inhibitors such as gemfibrozil.
  • Avoid in severe liver impairment.
  • Hyperthyroidism occurred in about 1% of adults on tablets.
  • In children, monitor growth.

Selexipag interactions

▾

Medicines that affect the CYP2C8 enzyme change selexipag levels.

  • Gemfibrozil (strong CYP2C8 inhibitor): contraindicated, as it greatly raises active drug levels.
  • Clopidogrel, deferasirox, teriflunomide: raise active drug levels, so dosing is cut to once daily.
  • Rifampin: lowers active drug levels, so the dose may be raised.

Interactions listed in the FDA-approved label

From the Selexipag prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox, teriflunomide): Increase exposure to the active metabolite of selexipag; clopidogrel increased active metabolite exposure approximately 2.7-fold with no relevant effect on selexipag exposure. Reduce the dosing of selexipag to once daily.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): Gemfibrozil doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant administration is contraindicated.
  • CYP2C8 inducers (e.g., rifampin): Rifampin halved exposure to the active metabolite. Increase up to twice the dose of selexipag when co-administered with rifampin; reduce selexipag when rifampin is stopped.
Read the label’s full interactions text

7 DRUG INTERACTIONS Moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox and teriflunomide) increase exposure to the active metabolite of selexipag. Reduce the dosing of selexipag to once daily ( 2.6 , 7.1 , 12.3 ). CYP2C8 inducers (e.g., rifampin) decrease exposure to the active metabolite. Increase up to twice the dose of selexipag ( 7.2 , 12.3 ). 7.1 CYP2C8 Inhibitors Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled the exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant administration of selexipag with strong inhibitors of CYP2C8 (e.g., gemfibrozil) is contraindicated [see Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )] . Concomitant administration of selexipag tablets with clopidogrel, a moderate inhibitor of CYP2C8, had no relevant effect on the exposure to selexipag and increased the exposure to the active metabolite by approximately 2.7-fold [see Clinical Pharmacology ( 12.3 )] . Reduce the dosing of selexipag to once daily in patients on a moderate CYP2C8 inhibitor [see Dosage and Administration ( 2.6 )] . 7.2 CYP2C8 Inducers Concomitant administration with an inducer of CYP2C8 and UGT 1A3 and 2B7 enzymes (rifampin) halved exposure to the active metabolite. Increase dose up to twice of selexipag when co-administered with rifampin. Reduce selexipag when rifampin is stopped [see Clinical Pharmacology ( 12.3 )] .

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿291 supplements and herbs with documented Selexipag interactions, ranked by severity Check Selexipag against a supplement or herb →

Before taking Selexipag

▾
  • Allergy to selexipag or its ingredients rules it out.
  • Tell your prescriber about every medicine you take.
  • Moderate liver impairment: once-daily dosing. Severe liver impairment: avoid.
  • Kidney: no adjustment needed with eGFR of 15 mL/min or higher.
  • Pregnancy: no adequate studies. Animal studies showed no clinically relevant effects on development.
  • Breastfeeding: stop the medicine or nursing.
  • Children under 2: safety and effectiveness not established.

Selexipag overdose

▾

Isolated adult overdoses with tablets, up to 3,200 mcg, caused only mild, short-lived nausea. In an overdose, supportive care is given. Dialysis is unlikely to help because the drug is highly protein-bound.

What Selexipag does in the body

▾

At the highest tolerated dose, Uptravi did not meaningfully prolong the QT interval (a heart rhythm measure). At clinically relevant levels it did not affect platelet aggregation. In a study of adults with PAH, it lowered pulmonary vascular resistance by about 30% and raised cardiac index compared to placebo.

How your body processes Selexipag

▾

About 49% of an oral dose is absorbed. Peak levels of selexipag occur in about 1–3 hours and of the active form in 3–4 hours. Food delays absorption and lowers the peak by about 30%, without changing total exposure.

The liver and intestine convert it to its active form, and CYP2C8 is the main enzyme involved in further breakdown. The active form's half-life is about 6–14 hours. Most of the drug leaves in the feces.

How to store Selexipag

▾

Store at 20 °C to 25 °C (68 °F to 77 °F). for UPTRAVI 100 mcg and 150 mcg tablets: Store and dispense in the original package to protect from moisture. Keep out of reach of children.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

291

Supplements & herbs that interact with Selexipag

291 supplements and herbal products have documented interactions with Selexipag in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 6
  • Moderate · 258
  • Minor · 27
ACTIVATED CHARCOAL Major AMERICAN HELLEBORE Major AMERICAN MISTLETOE Major DANSHEN Major PIRACETAM Major TYRAMINE Major ACONITE Moderate ADRAFINIL Moderate +283 more
Every supplement checked against Selexipag — ranked by severity The full interaction hub: 6 major · 258 moderate · 27 minor · every one linked to its full report. Check Selexipag against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

1

Nutrient depletion considerations

Selexipag has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

COENZYME Q10 Insufficient Evidence
See the full Selexipag nutrient depletion report

Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.

Selexipag: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Selexipag — the kind of thing our pharmacy team would talk through with you at the counter.

What is this medicine for?

▾
Selexipag treats pulmonary arterial hypertension, a type of high blood pressure in the arteries of your lungs. It helps delay the disease getting worse and lowers the chance you'll need to be hospitalized for it.

How should I take it?

▾
Tablets are taken by mouth twice a day and swallowed whole, so don't split or crush them. Taking them with food may help you tolerate them. Your doctor will raise your dose slowly, so follow their schedule closely.

What side effects should I expect?

▾
Headache, diarrhea, nausea, jaw pain and muscle aches are common, especially while your dose is going up. Tell your doctor or pharmacist if they become hard to handle, since the dose can be lowered to what you tolerate.

When should I call my doctor?

▾
Call right away if you have new or worsening shortness of breath, which could be fluid in the lungs. Also report symptoms that might suggest an overactive thyroid, or signs of an allergic reaction.

Are there medicines I should avoid with it?

▾
Yes. Gemfibrozil must never be taken with selexipag. Clopidogrel, deferasirox and teriflunomide call for a lower, once-daily schedule, while rifampin may need a higher dose. Always check with me before starting anything new.

Is it safe in pregnancy or while breastfeeding?

▾
There are no adequate studies in pregnant women, and PAH itself carries risks in pregnancy, so talk with your doctor. It isn't known whether the drug passes into breast milk, so you would need to stop either nursing or the medicine.

Is Selexipag available over the counter?

▾
No. Selexipag is a prescription medicine: every Selexipag product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Selexipag first available?

▾
The earliest FDA record we hold for Selexipag is from 2015: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Selexipag was first used.

Who makes Selexipag?

▾
3 companies currently list Selexipag products in the FDA's NDC Directory, including Actelion Pharmaceuticals US, Inc., Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Selexipag on HelloPharmacist

📊Selexipag supplement interactions291 checked — ranked by severity 🌿Drug & Supplement CheckerSelexipag vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Selexipag NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Selexipag Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Selexipag forms and strengths (how it comes)

Selexipag is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Uptravi
How this form is used
What it may be used for
  • Uptravi tablets treat PAH in adults and in children aged 2 years and older.
  • Selexipag tablets treat PAH to delay disease progression and reduce the risk of hospitalization.
Important instructions
  • Uptravi tablets are taken by mouth twice daily and swallowed whole, not split or crushed.
  • Uptravi tablets may be better tolerated when taken with food.
  • Uptravi tablet doses are raised step by step to the highest tolerated dose.
Available strengths 10 strengths
100 mcg 150 mcg 200 mcg 400 mcg 600 mcg 800 mcg
Show 4 more strengths Show fewer strengths
1000 mcg 1200 mcg 1400 mcg 1600 mcg
42 FDA-listed product records ⓘ

Capsule

By mouth
Available strengths 2 strengths
0.2 mg 0.8 mg
3 FDA-listed product records ⓘ

Injection

Into a vein
Brands Uptravi
How this form is used
What it may be used for
  • Uptravi for injection is used in adults with PAH (WHO Group I).
Important instructions
  • Uptravi for injection is given by intravenous infusion, twice daily.
  • Uptravi for injection dose is determined by the patient's current dose of Uptravi tablets.
Available strengths 1 strength
1800 mcg/10 mL
3 FDA-listed product records ⓘ

Selexipag on the U.S. market: products, makers and brands

How Selexipag appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

3 companies list 30 Selexipag product records with the FDA, mostly as tablet, capsule, injection; the earliest marketing or approval year on record is 2015. Brand names on the directory include Uptravi, UPTRAVI Titration Pack, Selexipag TITRATION PACK; the rest are generics.

3
Dose forms ⓘ
3
Labelers (makers, repackagers, distributors)
4
Brand names
30
FDA-listed product records ⓘ
2015
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (7) · Kit (6) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Actelion Pharmaceuticals US, Inc.40%
Zydus Lifesciences Limited30%
Zydus Pharmaceuticals (USA) Inc.30%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Selexipag is used (Medicaid data)

A general measure of how commonly Selexipag is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Selexipag is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

8,761
Medicaid prescriptions filled (Q1–Q4 2025)
$206.3M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Selexipag prescribed? Of the 1,601 medications we measure, Selexipag ranks #950 by Medicaid prescriptions — more than 41% of them.

Where Selexipag ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #950 of 1,601
#945 Aminophylline 9,002 Rx #946 Estradiol Topical 8,927 Rx #947 Eptinezumab-jjmr Injec... 8,909 Rx #948 Pitavastatin 8,812 Rx #949 Balsalazide 8,799 Rx #950 Selexipag 8,761 Rx #951 Nitroglycerin Topical 8,740 Rx #952 Fulvestrant Injection 8,707 Rx #953 Fulvestrant 8,707 Rx #954 Beclomethasone Nasal S... 8,632 Rx #955 Cetuximab Injection 8,583 Rx

Utilization by Selexipag product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 1.6 mg oral tablet is the most-dispensed Selexipag product — about 46% of these Medicaid prescriptions.

selexipag 1.6 MG Oral Tablet Most dispensed

4,000 Medicaid prescriptions (Q1–Q4 2025) 46% of Selexipag prescriptions shown $93.9M gross reimbursement (before rebates) ≈ $23,466 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1729045

selexipag 0.8 MG Oral Tablet

1,206 Medicaid prescriptions (Q1–Q4 2025) 14% of Selexipag prescriptions shown $26.2M gross reimbursement (before rebates) ≈ $21,758 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1729063

selexipag 0.2 MG Oral Tablet

1,171 Medicaid prescriptions (Q1–Q4 2025) 13% of Selexipag prescriptions shown $30.5M gross reimbursement (before rebates) ≈ $26,069 per prescription (gross)

Summed across the 2 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1729051

selexipag 1.2 MG Oral Tablet

636 Medicaid prescriptions (Q1–Q4 2025) 7% of Selexipag prescriptions shown $14.6M gross reimbursement (before rebates) ≈ $22,935 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1729027

selexipag 1 MG Oral Tablet

606 Medicaid prescriptions (Q1–Q4 2025) 7% of Selexipag prescriptions shown $13.6M gross reimbursement (before rebates) ≈ $22,452 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1729007

selexipag 0.6 MG Oral Tablet

505 Medicaid prescriptions (Q1–Q4 2025) 6% of Selexipag prescriptions shown $10.6M gross reimbursement (before rebates) ≈ $21,047 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1729059

selexipag 0.4 MG Oral Tablet

235 Medicaid prescriptions (Q1–Q4 2025) 3% of Selexipag prescriptions shown $5.2M gross reimbursement (before rebates) ≈ $21,927 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1729055

selexipag 1.4 MG Oral Tablet

165 Medicaid prescriptions (Q1–Q4 2025) 2% of Selexipag prescriptions shown $3.6M gross reimbursement (before rebates) ≈ $21,693 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1729031

Other Selexipag products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)

237 Medicaid prescriptions (Q1–Q4 2025) 3% of Selexipag prescriptions shown $8.2M gross reimbursement (before rebates) ≈ $34,435 per prescription (gross)

Summed across the 1 of 16 listed NDC products with Medicaid activity.

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Selexipag, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 10 of 46 listed Selexipag NDCs with Medicaid activity.

Compare Selexipag products

A representative set of FDA-listed product records for Selexipag — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 30 of 30 products — FDA National Drug Code Directory. See every product, package size and price: browse all 30 Selexipag NDCs →

Selexipag recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Selexipag recalls since July 2021.

✅No Selexipag recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Selexipag RxCUI 1729002 2 dose forms · 11 strengths
  1. Dose form (SCDF) Injection RxCUI 2565270 In current FDA listings
    Clinical drug / strength (SCD) 1.8 MG RxCUI 2565271
  2. Dose form (SCDF) Oral Tablet RxCUI 1729006 In current FDA listings
    Clinical drug / strength (SCD) 0.1 MG RxCUI 2744282 0.15 MG RxCUI 2744286 0.2 MG RxCUI 1729051 0.4 MG RxCUI 1729055 0.6 MG RxCUI 1729059 0.8 MG RxCUI 1729063 1 MG RxCUI 1729007 1.2 MG RxCUI 1729027 1.4 MG RxCUI 1729031 1.6 MG RxCUI 1729045

Look up RxCUI 1729002 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Selexipag brand names

Selexipag is sold under 3 brand names in the FDA directory — Uptravi, UPTRAVI Titration Pack, Selexipag TITRATION PACK. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Uptravi UPTRAVI Titration Pack Selexipag TITRATION PACK

Who makes Selexipag: manufacturers and labelers

3 companies list Selexipag products with the FDA. By number of product records, the largest are Actelion Pharmaceuticals US, Inc., Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Actelion Pharmaceuticals US, Inc. 12 Zydus Lifesciences Limited 9 Zydus Pharmaceuticals (USA) Inc. 9

Selexipag drug class (RxNorm)

Selexipag belongs to the Prostacyclin Receptor Agonist class.

Pharmacologic class Prostacyclin Receptor Agonist
Drug family (ATC) Platelet aggregation inhibitors excl. heparin
How it works Prostacyclin Receptor Agonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Selexipag page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective May 28, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Selexipag.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Selexipag after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
3
Finished products in the current FDA directory
30
Companies listing them (makers, repackagers, distributors)
3
FDA labeler codes behind them ⓘ
3
Linked representative label ⓘ
Actelion Pharmaceuticals US, Inc.
Linked label effective
May 28, 2026
Composite sections available
22
Linked SPL Set ID
a7a23b87-f892-4e2c-8e2e-ebf841220f90
Linked SPL Document ID
7c54a125-9778-41f5-b92c-181711e22e06
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Actelion Pharmaceuticals US, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →